Molecular structure of L 006235, CAS Number: 294623-49-7
L 006235 (CAS 294623-49-7)
See product citations (1)
Alternate Names:
N-[1-[[(Cyanomethyl)amino]carbonyl] cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazo lyl]benzamide
Application:
L 006235 is a reversible and potent cathepsin K inhibitor that displays more than a 4000 fold selectivity over cathepsins B, L and S
CAS Number:
294623-49-7
Purity:
≥98%
Molecular Weight:
466.6
Molecular Formula:
C24H30N6O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
L 006235 is a reversible and potent cathepsin K inhibitor that displays more than a 4000 fold selectivity over cathepsins B, L and S. L-006,235 is a highly effective and orally available inhibitor of cathepsin K, a key enzyme involved in bone resorption. With a Ki(app) value of 0.2 nM, it demonstrates remarkable selectivity for cathepsin K over cathepsins B, -L, and -S, with Ki(app) values of 1 µM, 6 µM, and 47 µM, respectively.
L 006235 (CAS 294623-49-7) References
- Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. | Palmer, JT., et al. 2005. J Med Chem. 48: 7520-34. PMID: 16302794
- Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. | Falgueyret, JP., et al. 2005. J Med Chem. 48: 7535-43. PMID: 16302795
- The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. | Black, WC. and Percival, MD. 2006. Chembiochem. 7: 1525-35. PMID: 16921579
- Effect of cathepsin k inhibitor basicity on in vivo off-target activities. | Desmarais, S., et al. 2008. Mol Pharmacol. 73: 147-56. PMID: 17940194
- Comparison of MALDI to ESI on a triple quadrupole platform for pharmacokinetic analyses. | Volmer, DA., et al. 2007. Anal Chem. 79: 9000-6. PMID: 17944440
- Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. | Svelander, L., et al. 2009. Eur J Pharmacol. 613: 155-62. PMID: 19358841
- Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. | Pennypacker, BL., et al. 2011. J Bone Miner Res. 26: 252-62. PMID: 20734451
- Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. | Hayami, T., et al. 2012. Bone. 50: 1250-9. PMID: 22484689
- Effects of pharmacological inhibition of cathepsin K on fracture repair in mice. | Soung, do Y., et al. 2013. Bone. 55: 248-55. PMID: 23486186
- Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. | Pennypacker, BL., et al. 2013. BMC Musculoskelet Disord. 14: 344. PMID: 24321244
- Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. | Duong, LT., et al. 2014. Mol Cancer Ther. 13: 2898-909. PMID: 25249554
- Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain. | Nwosu, LN., et al. 2018. Pain Rep. 3: e685. PMID: 30706033
- The Role of Adipokines and Bone Marrow Adipocytes in Breast Cancer Bone Metastasis. | Shin, E. and Koo, JS. 2020. Int J Mol Sci. 21: PMID: 32674405
- Assessment of the circulatory concentrations of cathepsin D, cathepsin K, and alpha-1 antitrypsin in patients with knee osteoarthritis. | Khoshdel, A., et al. 2022. Ir J Med Sci.. PMID: 35749030
Inhibitor of:
cathepsin K.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L 006235, 10 mg | sc-361220 | 10 mg | $209.00 | |||
L 006235, 50 mg | sc-361220A | 50 mg | $882.00 |